All AmerisourceBergen articles
-
ArticleOpioid cases against retail pharmacy chains yield compliance lessons
Two cases involving five retail pharmacy chains winding their way through court foretell a long and costly road ahead for all companies across the pharmaceutical supply chain battling litigation for their alleged roles in fueling the opioid epidemic.
-
ArticleCompliance ramifications of proposed $26B opioid deal for pharma industry
Three major drug distributors and drugmaker Johnson & Johnson reached a proposed $26 billion multistate agreement for their alleged roles in fueling the nationwide opioid epidemic. The settlement imparts compliance lessons on the pharmaceutical industry at large.
-
ArticleDistilling compliance lessons from healthcare fraud cases
False Claims Act recoveries related to healthcare fraud in fiscal year 2018 offer key insight into the best practices the government expects to ensure compliance with federal healthcare laws.
-
Blog
AmerisourceBergen to pay $625M over illegally repackaged drugs
AmerisourceBergen and its subsidiaries have agreed to pay $625 million to resolve its civil liability to the United States under the False Claims Act for causing false claims for the drugs it repackaged to be submitted to federal health care programs.